The Jersey Journal
Bristol-Myers Squibb drug study showed effectiveness against advanced melanoma cancer
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Wed May 15, 2013
Bristol-Myers Squibb: The Caped Crusaders
Bristol-Myers Squibb's Joseph Campisi and Demetrios Kyonieus were virtually inseparable for eight months in 2012 while they negotiated an M&A deal that was large and complex.
Tue May 14, 2013
Bristol-Myers Squibb to Present at UBS Global Health Care Conference
Bristol-Myers Squibb Company will present at the UBS Global Health Care Conference on Tuesday, May 21, 2013, in New York City.
Mon May 13, 2013
Research and Markets: Bristol-Myers Squibb Partnering 2005-2013
This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years.
Bas Burger To Lead BT Operations In The US & Canada And Across Global Industry Sectors
BT announced the appointment of Bas Burger to the position of president of BT US & Canada and president for the Global Consumer Packaged Goods and the Global Pharmaceutical and Chemical industry sectors.
Thu May 09, 2013
Adaptive Biotechnologies Signs Biomarker Discovery Collaboration...
Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response.
Wed May 08, 2013
Drug Store News
Healthcare reform law provisions could affect pharmaceutical...
Drug maker Bristol-Myers Squibb foresees significant effects on its business from the Patient Protection and Affordable Care Act, company executives told attendees of the its recent shareholder meeting.
Sustiva (Efavirenz) Receives Us Fda Snda Approval For Use In HIV-1 Infected Pediatric Patients
Approval offers a once-daily option as part of a regimen for HIV-1 infected infants as young as three months and weighing at least 3.5 kg.
Tue May 07, 2013
National Center for Public Policy Res...
More on Bristol-Myers Squibb and ObamaCare...
ObamaCare Developments Could Have Major Impact on Leading Drugmaker Bristol-Myers Squibb Executive Tells National Center for Public Policy Research that the Company is Following IPAB Creation "Very Closely" Obama Administration "Dual-Eligibles" Rebate Plan, if Imposed, Could Have "Significant Impact" During "Pivot Year" for Bristol-Myers Squibb ... (more)
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation
ARISTOTLE studied Eliquis vs. warfarin for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation )-- Bristol-Myers Squibb Company and Pfizer Inc .
Fri May 03, 2013
Contract Pharma Breaking News
Ambrx, BMS in Next-Gen Antibody Pact
Ambrx and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.
Customer Interaction Solutions
Bristol-Myers Squibb Receives Us Fda sNDA Approval for Use of Sustiva ...
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA , including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.
Tue Apr 30, 2013
Report Published: "Bristol-Myers Squibb de Mexico SA de CV in Hot Drinks (Mexico)"
However, the company is not involved only in the manufacturing and sales of medicines in Mexico, but participates in other areas such as powder hot drinks with the very successful brands Cal-C-Tose and Choco Milk.
Mon Apr 29, 2013
Bristol Myers Squibb EPS Estimates Cut by Leerink Swann
The firm currently has a "market perform" rating on the company's shares. Several other analysts have also recently commented on the stock.
Sat Apr 27, 2013
Bristol Myers Squibb Price Target Raised to $29.00 at MKM Partners
The firm currently has a "sell" rating on the stock. The analysts noted that the move was a valuation call.
Bristol Myers Squibb Rating Reiterated by JPMorgan Chase
's stock had its "neutral" rating reiterated by equities research analysts at JPMorgan Chase in a research note issued to investors on Friday, AnalystRatingsNetwork.com reports.
Thu Apr 25, 2013
Time Warner Cable, Bristol-Myers, JetBlue earnings disappoint
Time Warner Cable, Bristol-Myers Squibb, and JetBlue earnings announcements disappointed Wall Street, while Colgate-Palmolive and New York Times stock gained despite profit declines.
Wed Apr 24, 2013
Bristol-Myers Squibb Preview: Performance Of New Drugs Is Key
Bristol-Myers Squibb is scheduled to announce its results for Q1 2013 on April 25.
Whisper Number Impact: Earnings Preview For Bristol-Myers Squibb
Bristol-Myers Squibb is expected to report earnings on Thursday, April 25th. The whisper number is $0.45, four cents ahead of the analysts' estimate.
FDA Discouraging Real-Time Release Testing as a Shortcut to End Testing, Experts Say
The US FDA is beginning to push CMOs and other manufacturers away from using real-time release testing as a shortcut to ensuring drug quality and reducing end product testing, experts said.